scholarly journals Clinical impact of 18 F-FDG-PET/CT in living donor liver transplantation for advanced hepatocellular carcinoma

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e541
Author(s):  
S.D. Lee ◽  
S.H. Kim ◽  
E.C. Lee ◽  
S.-J. Park ◽  
Y.-K. Kim ◽  
...  
2022 ◽  
Vol 11 (2) ◽  
pp. 354
Author(s):  
Sungmin Kang ◽  
Joo Dong Kim ◽  
Dong Lak Choi ◽  
Byungwook Choi

This study evaluated the prognostic value of metabolic parameters based on the standardized uptake value (SUV) normalized by total body weight (bwSUV) and by lean body mass (SUL) measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting tumor recurrence after primary living donor liver transplantation (LDLT) in patients with hepatocellular carcinoma (HCC) without transplantation locoregional therapy. This retrospective study enrolled 49 patients with HCC. The maximum tumor bwSUV (T-bwSUVmax) and SUL (T-SULmax) were measured on PET. The maximum bwSUV (L-bwSUVmax), mean bwSUV (L-bwSUVmean), maximum SUL (L-SULmax), and mean SUL (L-SULmean) were measured in the liver. All metabolic parameters were evaluated using survival analyses and compared to clinicopathological factors. Tumor recurrence occurred in 16/49 patients. Kaplan–Meier analysis revealed that all metabolic parameters were significant (p < 0.05). Univariate analysis revealed that prothrombin-induced by vitamin K absence or antagonist-II; T-stage; tumor number; tumor size; microvascular invasion; the Milan criteria, University of California, San Francisco (UCSF), and up-to-seven criteria; T-bwSUVmax/L-bwSUVmean; T-SULmax; T-SULmax/L-SULmax; and T-SULmax/L-SULmean were significant predictors. Multivariate analysis revealed that the T-SULmax/L-SULmean (hazard ratio = 115.6; p = 0.001; cut-off, 1.81) and UCSF criteria (hazard ratio = 172.1; p = 0.010) were independent predictors of tumor recurrence. SUL-based metabolic parameters, especially T-SULmax/L-SULmean, were significant, independent predictors of HCC recurrence post-LDLT.


2020 ◽  
Vol 04 (01) ◽  
pp. 031-035
Author(s):  
Martin I. Montenovo

AbstractHepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide and the third leading cause of cancer-related death. Despite the significant progress that has been achieved with local therapies, treatment remains limited by impaired liver function and high rate of recurrence. The purpose of the manuscript is to describe the current status of using living donor liver transplantation in patients with advanced HCC.


Sign in / Sign up

Export Citation Format

Share Document